Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Other Non-Current Liabilities (2021 - 2025)

Historic Other Non-Current Liabilities for Foghorn Therapeutics (FHTX) over the last 3 years, with Q3 2025 value amounting to $656000.0.

  • Foghorn Therapeutics' Other Non-Current Liabilities changed N/A to $656000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $656000.0, marking a year-over-year change of. This contributed to the annual value of $29000.0 for FY2022, which is 7972.03% down from last year.
  • Foghorn Therapeutics' Other Non-Current Liabilities amounted to $656000.0 in Q3 2025.
  • In the past 5 years, Foghorn Therapeutics' Other Non-Current Liabilities ranged from a high of $856000.0 in Q1 2025 and a low of $29000.0 during Q4 2022
  • In the last 3 years, Foghorn Therapeutics' Other Non-Current Liabilities had a median value of $143000.0 in 2021 and averaged $319333.3.
  • The largest annual percentage gain for Foghorn Therapeutics' Other Non-Current Liabilities in the last 5 years was 6608.19% (2022), contrasted with its biggest fall of 7972.03% (2022).
  • Over the past 3 years, Foghorn Therapeutics' Other Non-Current Liabilities (Quarter) stood at $143000.0 in 2021, then tumbled by 79.72% to $29000.0 in 2022, then skyrocketed by 2162.07% to $656000.0 in 2025.
  • Its last three reported values are $656000.0 in Q3 2025, $757000.0 for Q2 2025, and $856000.0 during Q1 2025.